Evolution of Pneumococcal Serotype Epidemiology in Botswana Following Introduction of 13-valent Pneumococcal Conjugate Vaccine

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2022 Jan 5

PMID 34986196

Citations 5

Authors

Sweta M Patel

Yazdani B Shaik-Dasthagirisaheb

Morgan Congdon

Rebecca R Young

Mohamed Z Patel

Tiny Mazhani

Sefelani Boiditswe

Tirayaone Leburu

Kwana Lechiile

Tonya Arscott-Mills

Andrew P Steenhoff

Kristen A Feemster

Samir S Shah

Coleen K Cunningham

Stephen I Pelton

Matthew S Kelly

Affiliations

Soon will be listed here.

Abstract

Pneumococcal conjugate vaccines reduce the burden of invasive pneumococcal disease, but the sustained effect of these vaccines can be diminished by an increase in disease caused by non-vaccine serotypes. To describe pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine (PCV-13) in July 2012, we performed molecular serotyping of 268 pneumococcal strains isolated from 221 children between 2012 and 2017. The median (interquartile range) age of the children included in this analysis was 6 (3,12) months. Fifty-nine percent of the children had received at least one dose of PCV-13 and 35% were fully vaccinated with PCV-13. While colonization by vaccine serotypes steadily declined following PCV-13 introduction, 25% of strains isolated more than 3 years after vaccine introduction were PCV-13 serotypes. We also observed an increase in colonization by non-vaccine serotypes 21 and 23B, which have been associated with invasive pneumococcal disease and antibiotic resistance in other settings.

Citing Articles

Long-term impact of 10-valent pneumococcal conjugate vaccine among children <5 years, Uganda, 2014-2021.

Wanyana M, Migisha R, King P, Bulage L, Kwesiga B, Kadobera D PLOS Glob Public Health. 2025; 5(1):e0002980.

PMID: 39761235 PMC: 11703042. DOI: 10.1371/journal.pgph.0002980.

Serotype epidemiology and antibiotic resistance of pneumococcal isolates colonizing infants in Botswana (2016-2019).

Hurst J, Shaik-Dasthagirisaheb Y, Truong L, Boiditswe S, Patel S, Gilchrist J PLoS One. 2024; 19(5):e0302400.

PMID: 38787847 PMC: 11125537. DOI: 10.1371/journal.pone.0302400.

Invasive pneumococcal disease serotype 23B1 causing multifocal septic arthritis, myositis and retroperitoneal abscess.

Drummond K, Holmes N BMJ Case Rep. 2024; 17(1).

PMID: 38233006 PMC: 10806890. DOI: 10.1136/bcr-2023-257318.

Changes in Invasive Pneumococcal Disease in the Paediatric Population in the Second COVID-19 Pandemic Year.

Izquierdo C, Ciruela P, Soldevila N, Garcia-Garcia J, Gonzalez-Peris S, Diaz-Conradi A Vaccines (Basel). 2023; 11(10).

PMID: 37896951 PMC: 10611414. DOI: 10.3390/vaccines11101548.

Kinetics of pneumococcal antibodies among HIV-exposed, uninfected infants in Botswana.

Uffman E, Li S, Chen J, Allen N, Boiditswe S, Fouda G Vaccine. 2022; 40(33):4764-4771.

PMID: 35773120 PMC: 9912097. DOI: 10.1016/j.vaccine.2022.06.059.

References

Madhi S, Moreira M, Koen A, van Niekerk N, de Gouveia L, Jose L . Impact of HIV status and vaccination schedule on bacterial nasopharyngeal carriage following infant immunisation with the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in South Africa. Vaccine. 2020; 38(10):2350-2360. DOI: 10.1016/j.vaccine.2020.01.062. View

Hausdorff W, Feikin D, Klugman K . Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005; 5(2):83-93. DOI: 10.1016/S1473-3099(05)01280-6. View

van Hoek A, Sheppard C, Andrews N, Waight P, Slack M, Harrison T . Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine. 2014; 32(34):4349-55. DOI: 10.1016/j.vaccine.2014.03.017. View

Kaplan S, Barson W, Lin P, Romero J, Bradley J, Tan T . Invasive Pneumococcal Disease in Children's Hospitals: 2014-2017. Pediatrics. 2019; 144(3). DOI: 10.1542/peds.2019-0567. View

Kelly M, Smieja M, Luinstra K, Wirth K, Goldfarb D, Steenhoff A . Association of respiratory viruses with outcomes of severe childhood pneumonia in Botswana. PLoS One. 2015; 10(5):e0126593. PMC: 4431806. DOI: 10.1371/journal.pone.0126593. View

Turner P, Leab P, Ly S, Sao S, Miliya T, Heffelfinger J . Impact of 13-Valent Pneumococcal Conjugate Vaccine on Colonization and Invasive Disease in Cambodian Children. Clin Infect Dis. 2019; 70(8):1580-1588. PMC: 7145996. DOI: 10.1093/cid/ciz481. View

Pimenta F, Roundtree A, Soysal A, Bakir M, du Plessis M, Wolter N . Sequential triplex real-time PCR assay for detecting 21 pneumococcal capsular serotypes that account for a high global disease burden. J Clin Microbiol. 2012; 51(2):647-52. PMC: 3553924. DOI: 10.1128/JCM.02927-12. View

Dube F, Ramjith J, Gardner-Lubbe S, Nduru P, Robberts F, Wolter N . Longitudinal characterization of nasopharyngeal colonization with Streptococcus pneumoniae in a South African birth cohort post 13-valent pneumococcal conjugate vaccine implementation. Sci Rep. 2018; 8(1):12497. PMC: 6104038. DOI: 10.1038/s41598-018-30345-5. View

Swarthout T, Fronterre C, Lourenco J, Obolski U, Gori A, Bar-Zeev N . High residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi. Nat Commun. 2020; 11(1):2222. PMC: 7203201. DOI: 10.1038/s41467-020-15786-9. View

10.

Weinberger D, Bruden D, Grant L, Lipsitch M, OBrien K, Pelton S . Using pneumococcal carriage data to monitor postvaccination changes in invasive disease. Am J Epidemiol. 2013; 178(9):1488-95. PMC: 3813314. DOI: 10.1093/aje/kwt156. View

11.

Bliss S, OBrien K, Janoff E, Cotton M, Musoke P, Coovadia H . The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect Dis. 2007; 8(1):67-80. DOI: 10.1016/S1473-3099(07)70242-6. View

12.

Voysey M, Fanshawe T, Kelly D, OBrien K, Kandasamy R, Shrestha S . Serotype-Specific Correlates of Protection for Pneumococcal Carriage: An Analysis of Immunity in 19 Countries. Clin Infect Dis. 2017; 66(6):913-920. DOI: 10.1093/cid/cix895. View

13.

Wouters I, Desmet S, van Heirstraeten L, Blaizot S, Verhaegen J, Van Damme P . Follow-up of serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae in child carriage after a PCV13-to-PCV10 vaccine switch in Belgium. Vaccine. 2019; 37(8):1080-1086. DOI: 10.1016/j.vaccine.2018.12.068. View

14.

Heinsbroek E, Tafatatha T, Phiri A, Swarthout T, Alaerts M, Crampin A . Pneumococcal carriage in households in Karonga District, Malawi, before and after introduction of 13-valent pneumococcal conjugate vaccination. Vaccine. 2018; 36(48):7369-7376. PMC: 6238076. DOI: 10.1016/j.vaccine.2018.10.021. View

15.

Whelan F, Verschoor C, Stearns J, Rossi L, Luinstra K, Loeb M . The loss of topography in the microbial communities of the upper respiratory tract in the elderly. Ann Am Thorac Soc. 2014; 11(4):513-21. DOI: 10.1513/AnnalsATS.201310-351OC. View

16.

Congdon M, Hong H, Young R, Cunningham C, Enane L, Arscott-Mills T . Effect of Haemophilus influenzae Type b and 13-Valent Pneumococcal Conjugate Vaccines on Childhood Pneumonia Hospitalizations and Deaths in Botswana. Clin Infect Dis. 2020; 73(2):e410-e416. PMC: 8282259. DOI: 10.1093/cid/ciaa919. View

17.

Rodenburg G, De Greeff S, Jansen A, de Melker H, Schouls L, Hak E . Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis. 2010; 16(5):816-23. PMC: 2953990. DOI: 10.3201/eid1605.091223. View